Paroxysmal Nocturnal Hemoglobinuria Market, By Drugs (Pozelimab + Cemdisiran, Ravulizumab (ULTOMIRIS), Zaltenibart (OMS906), Pegcetacoplan (EMPAVELI/ASPAVELI), Iptacopan (FABHALTA), Crovalimab (PIASKY), Eculizumab (SOLIRIS) and Danicopan (VOYDEYA)), By Class of Therapies, By Epidemiology, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
|
Report ID
ANV6320
|
Published Date
November 2026
|
Pages
301
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Paroxysmal Nocturnal Hemoglobinuria market size was valued at US$ 5,890.1 Million in 2025, expanding at a CAGR of 9.9% from 2026 to 2033.
Paroxysmal nocturnal hemoglobinuria is a rare blood disease caused by a genetic mutation that causes a person\'s body to attack red blood cells through his body\'s immune system, which involves the complement system. There is no protection for red blood cells from immune attacks due to the absence of certain proteins on the surface of these cells; patients with paroxysmal nocturnal hemoglobinuria will experience frequent instances of hemolysis. Symptoms include anemia, tiredness, dark-colored urine, stomach pain, kidney-related disorders, and an increased risk of blood clots. Since the condition is chronic in nature, medical intervention is needed in order to prevent the development of complications and enhance patients\' quality of life. Hence, continuous medical management and effective treatment are necessary to prevent complications, control hemolysis, and improve patients\' well-being.
Paroxysmal Nocturnal Hemoglobinuria Market- Market Dynamics
Increasing prevalence and diagnosis of disorders to drive market demand
The growing prevalence and diagnosis of Paroxysmal Nocturnal Hemoglobinuria (PNH) will contribute to the increase in the need for the diagnosis of diseases, diagnostic testing, and treatment, hence the development of new drugs for patients. In October 2026, according to the UK Government’s Independent Review into Mental Health Conditions, ADHD and autism, common adult mental health disorders, rose from 15.5% to 22.6% in adults aged between 16 and 64 years. ADHD rose by six times in children aged between 6 and 11 years, from 0.45% to 2.70%, and also rose from 0.26% to 3.88% in children aged between 12 and 17 years. Children aged between 6 and 11 years also had an increase in prevalence of autism from 0.24% to 4.58%. Referrals for assessment of ADHD have also increased more than three-fold to 17,000 per month from 5,000. This shows that there is an increased demand for diagnosis. These rising prevalence rates are increasing the need for early diagnosis, improved healthcare services, and effective treatment options.
Paroxysmal Nocturnal Hemoglobinuria Market- Segmentation Analysis:
The Global Paroxysmal Nocturnal Hemoglobinuria market is segmented on the basis of Drugs, Class of Therapies, Epidemiology, and Region.
Among the given treatment types, complement inhibitors hold a leading position in the market. These drugs work by targeting specific components of the complement system, like C5, C3, or factors B and D, which prevent red blood cell destruction. Now they are the golden standard of the treatment of hemolysis and replace other treatment methods, such as blood transfusion and supportive treatment. In January 2025, Alexion Pharmaceuticals (AstraZeneca) released the results of the long-term outcome of the Phase III ALPHA clinical trial of Voydeya (danicopan)—an oral factor D inhibitor taken along with Ultomiris/Soliris for the treatment of PNH patients with clinically significant extravascular hemolysis. The drug managed to provide sustained improvement of hemoglobin and control of hemolysis. This provides more opportunities for the control of the disease due to the suppression of hemolysis, increased sustained hemoglobin levels, and treatment of PNH patients.
Paroxysmal Nocturnal Hemoglobinuria Market- Geographical Insights
North America remains a key player in the global Paroxysmal Nocturnal Hemoglobinuria market due to advanced diagnostic capabilities for rare disorders, faster introduction of innovative therapies, favorable orphan drug reimbursement policies, and the presence of key players in the market sector. In September 2025, in the NIH gov database, 231 out of 326 orphan drugs approved by the U.S. FDA (70.9%) were also approved by Health Canada for the same indications.
The study showed a median approval lag time of 346 days [181-785 days]. In addition to the above, the government of Canada is determined to invest $1.5 billion over the next three years for better access to drugs for rare diseases. Out of 213 orphan drugs approved by Health Canada that were subject to therapeutic assessment, 187 (87.8%) have undergone therapeutic evaluations, and 50 (26.7%) showed major additional therapeutic value. These developments underscore how funding strategies and reimbursement policies are increasingly vital for improving orphan drug access in Canada.
Europe also holds a strong position in this market due to having very good policies for rare diseases, excellent health care infrastructures, and more investment in research. For example, in February 2026, the European Union reported that it was stated that 27-36 million people suffer from rare diseases within the European Union and that the number of rare diseases stands at 6,000-8,000. 70% of rare diseases are childhood ailments, and 95% of them have no treatment at all. A number of rare-disease policies have been put forward by the EU, which includes the incentives for developing orphan drugs, national plans, centers of excellence, cross-border healthcare, and research collaboration. Additionally, the assessment mentions 31 potential actions in 6 important themes to improve rare disease policies and increase access to treatment and collaboration among the 27 member states of the EU. This will continue to improve research into rare diseases in Europe and lead to innovative treatment options.
Paroxysmal Nocturnal Hemoglobinuria Market- Competitive Landscape:
The global Paroxysmal Nocturnal Hemoglobinuria market is quite concentrated, with a few key biopharma players competing within the complement pathway space. These key players include Alexion (AstraZeneca Rare Disease), Novartis AG, Apellis Pharmaceuticals, F. Hoffmann-La Roche (in collaboration with Chugai), and Swedish Orphan Biovitrum (Sobi). The competition in the market is increasing among the key players as they are offering greater convenience, higher dosing, and also the capacity to treat both intravascular and extravascular hemolysis. In March 2026, Biogen decided to acquire Apellis Pharmaceuticals for $5.6 billion. This indicates that there are many large companies who have invested heavily in the development of complement pathway therapies. There will be the development of new mechanisms and more tolerable treatments that will enter the market.
Recent Developments:
- In October 2025, Novo Nordisk and Omeros announced that they had entered an asset acquisition and licensing agreement whereby Novo Nordisk obtained exclusive worldwide rights to the MASP-3 inhibitor zaltenibart, which is being developed for the treatment of PNH. Omeros can receive milestone payments of up to US$2.1 billion. Novo Nordisk is planning to launch a global Phase 3 trial in PNH.
- In June 2025, Novartis announced that its Phase 3B APPULSE-PNH trial using Fabhalta (iptacopan) as monotherapy twice daily in adult patients with PNH was successful.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- AstraZeneca plc
- Apellis Pharmaceuticals, Inc.
- Swedish Orphan Biovitrum AB (Sobi)
- Novartis AG
- Hoffmann-La Roche Ltd
- Chugai Pharmaceutical Co., Ltd.
- Regeneron Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals, Inc.
- Novo Nordisk A/S
- Omeros Corporation
- Samsung Bioepis Co., Ltd.
- Amgen Inc.
- Akari Therapeutics plc
- BioCryst Pharmaceuticals, Inc.
- NovelMed Therapeutics
- Sanofi
- Others
GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA MARKET, BY DRUGS- MARKET ANALYSIS, 2020 - 2033
- Pozelimab + Cemdisiran
- Ravulizumab (ULTOMIRIS)
- Zaltenibart (OMS906)
- Pegcetacoplan (EMPAVELI/ASPAVELI)
- Iptacopan (FABHALTA)
- Crovalimab (PIASKY)
- Eculizumab (SOLIRIS)
- Danicopan (VOYDEYA)
GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA MARKET, BY CLASS OF THERAPIES- MARKET ANALYSIS, 2020 - 2033
- MASP-3 Inhibitors
- Complement C3 Inhibitors
- Complement C5 Inhibitors
- Complement Factor B Inhibitors
- Complement Factor D Inhibitors
GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA MARKET, BY EPIDEMIOLOGY- MARKET ANALYSIS, 2020 - 2033
- Total Treated Cases
- Total Diagnosed Prevalent Cases
- Age-Specific Cases
- Gender-Specific Cases
GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
TABLE OF CONTENT
1. Paroxysmal Nocturnal Hemoglobinuria Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.2. Competitive Insights
3. Paroxysmal Nocturnal Hemoglobinuria Key Market Trends
3.1. Paroxysmal Nocturnal Hemoglobinuria Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Paroxysmal Nocturnal Hemoglobinuria Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Paroxysmal Nocturnal Hemoglobinuria Market Opportunities
3.4. Paroxysmal Nocturnal Hemoglobinuria Market Future Trends
4. Paroxysmal Nocturnal Hemoglobinuria Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Paroxysmal Nocturnal Hemoglobinuria Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Paroxysmal Nocturnal Hemoglobinuria Market Landscape
6.1. Paroxysmal Nocturnal Hemoglobinuria Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Paroxysmal Nocturnal Hemoglobinuria Market – By Drugs
7.1. Overview
7.1.1. Segment Share Analysis, By Drugs, 2025 & 2033 (%)
7.1.2. Pozelimab + Cemdisiran
7.1.3. Ravulizumab (ULTOMIRIS)
7.1.4. Zaltenibart (OMS906)
7.1.5. Pegcetacoplan (EMPAVELI/ASPAVELI)
7.1.6. Iptacopan (FABHALTA)
7.1.7. Crovalimab (PIASKY)
7.1.8. Eculizumab (SOLIRIS)
7.1.9. Danicopan (VOYDEYA)
8. Paroxysmal Nocturnal Hemoglobinuria Market – By Class of Therapies
8.1. Overview
8.1.1. Segment Share Analysis, By Class of Therapies, 2025 & 2033 (%)
8.1.2. MASP-3 Inhibitors
8.1.3. Complement C3 Inhibitors
8.1.4. Complement C5 Inhibitors
8.1.5. Complement Factor B Inhibitors
8.1.6. Complement Factor D Inhibitors
9. Paroxysmal Nocturnal Hemoglobinuria Market – By Epidemiology
9.1. Overview
9.1.1. Segment Share Analysis, By Epidemiology, 2025 & 2033 (%)
9.1.2. Total Treated Cases
9.1.3. Total Diagnosed Prevalent Cases
9.1.4. Age-Specific Cases
9.1.5. Gender-Specific Cases
10. Paroxysmal Nocturnal Hemoglobinuria Market – By Geography
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
10.2. North America
10.2.1. Overview
10.2.2. Paroxysmal Nocturnal Hemoglobinuria Key Manufacturers in North America
10.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.2.4. North America Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.2.5. North America Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.2.6. North America Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.2.7. U.S.
10.2.7.1. Overview
10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.2.7.3. U.S. Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.2.7.4. U.S. Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.2.7.5. U.S. Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.2.8. Canada
10.2.8.1. Overview
10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.2.8.3. Canada Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.2.8.4. Canada Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.2.8.5. Canada Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.3. Europe
10.3.1. Overview
10.3.2. Paroxysmal Nocturnal Hemoglobinuria Key Manufacturers in Europe
10.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.3.4. Europe Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.3.5. Europe Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.3.6. Europe Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.3.7. Germany
10.3.7.1. Overview
10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.7.3. Germany Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.3.7.4. Germany Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.3.7.5. Germany Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.3.8. UK
10.3.8.1. Overview
10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.8.3. UK Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.3.8.4. UK Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.3.8.5. UK Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.3.9. France
10.3.9.1. Overview
10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.9.3. France Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.3.9.4. France Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.3.9.5. France Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.3.10. Italy
10.3.10.1. Overview
10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.10.3. Italy Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.3.10.4. Italy Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.3.10.5. Italy Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.3.11. Spain
10.3.11.1. Overview
10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.11.3. Spain Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.3.11.4. Spain Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.3.11.5. Spain Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.3.12. The Netherlands
10.3.12.1. Overview
10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.12.3. The Netherlands Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.3.12.4. The Netherlands Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.3.12.5. The Netherlands Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.3.13. Sweden
10.3.13.1. Overview
10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.13.3. Sweden Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.3.13.4. Sweden Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.3.13.5. Sweden Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.3.14. Russia
10.3.14.1. Overview
10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.14.3. Russia Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.3.14.4. Russia Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.3.14.5. Russia Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.3.15. Poland
10.3.15.1. Overview
10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.15.3. Poland Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.3.15.4. Poland Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.3.15.5. Poland Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.3.16. Denmark
10.3.16.1. Overview
10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.16.3. Denmark Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.3.16.4. Denmark Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.3.16.5. Denmark Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.3.17. Rest of Europe
10.3.17.1. Overview
10.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.17.3. Rest of the Europe Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.3.17.4. Rest of the Europe Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.3.17.5. Rest of the Europe Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.4. Asia Pacific (APAC)
10.4.1. Overview
10.4.2. Paroxysmal Nocturnal Hemoglobinuria Key Manufacturers in Asia Pacific
10.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.4.4. APAC Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.4.5. APAC Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.4.6. APAC Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.4.7. China
10.4.7.1. Overview
10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.7.3. China Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.4.7.4. China Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.4.7.5. China Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.4.8. India
10.4.8.1. Overview
10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.8.3. India Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.4.8.4. India Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.4.8.5. India Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.4.9. Japan
10.4.9.1. Overview
10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.9.3. Japan Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.4.9.4. Japan Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.4.9.5. Japan Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.4.10. South Korea
10.4.10.1. Overview
10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.10.3. South Korea Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.4.10.4. South Korea Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.4.10.5. South Korea Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.4.11. Australia
10.4.11.1. Overview
10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.11.3. Australia Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.4.11.4. Australia Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.4.11.5. Australia Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.4.12. Indonesia
10.4.12.1. Overview
10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.12.3. Indonesia Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.4.12.4. Indonesia Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.4.12.5. Indonesia Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.4.13. Thailand
10.4.13.1. Overview
10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.13.3. Thailand Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.4.13.4. Thailand Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.4.13.5. Thailand Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.4.14. Philippines
10.4.14.1. Overview
10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.14.3. Philippines Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.4.14.4. Philippines Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.4.14.5. Philippines Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.4.15. Taiwan
10.4.15.1. Overview
10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.15.3. Taiwan Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.4.15.4. Taiwan Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.4.15.5. Taiwan Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.4.16. Vietnam
10.4.16.1. Overview
10.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.16.3. Vietnam Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.4.16.4. Vietnam Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.4.16.5. Vietnam Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.4.17. Rest of APAC
10.4.17.1. Overview
10.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.17.3. Rest of APAC Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.4.17.4. Rest of APAC Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.4.17.5. Rest of APAC Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.5. Latin America (LATAM)
10.5.1. Overview
10.5.2. Paroxysmal Nocturnal Hemoglobinuria Key Manufacturers in Latin America
10.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.5.4. LATAM Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.5.5. LATAM Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.5.6. LATAM Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.5.7. Brazil
10.5.7.1. Overview
10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.7.3. Brazil Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.5.7.4. Brazil Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.5.7.5. Brazil Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.5.8. Mexico
10.5.8.1. Overview
10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.8.3. Mexico Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.5.8.4. Mexico Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.5.8.5. Mexico Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.5.9. Argentina
10.5.9.1. Overview
10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.9.3. Argentina Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.5.9.4. Argentina Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.5.9.5. Argentina Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.5.10. Colombia
10.5.10.1. Overview
10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.10.3. Colombia Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.5.10.4. Colombia Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.5.10.5. Colombia Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.5.11. Rest of LATAM
10.5.11.1. Overview
10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.11.3. Rest of LATAM Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.5.11.4. Rest of LATAM Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.5.11.5. Rest of LATAM Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.6. Middle East and Africa (MEA)
10.6.1. Overview
10.6.2. Paroxysmal Nocturnal Hemoglobinuria Key Manufacturers in Middle East and Africa
10.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.6.4. MEA Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.6.5. MEA Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.6.6. MEA Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.6.7. Saudi Arabia
10.6.7.1. Overview
10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.7.3. Saudi Arabia Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.6.7.4. Saudi Arabia Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.6.7.5. Saudi Arabia Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.6.8. UAE
10.6.8.1. Overview
10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.8.3. UAE Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.6.8.4. UAE Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.6.8.5. UAE Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.6.9. Israel
10.6.9.1. Overview
10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.9.3. Israel Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.6.9.4. Israel Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.6.9.5. Israel Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.6.10. Turkey
10.6.10.1. Overview
10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.10.3. Turkey Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.6.10.4. Turkey Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.6.10.5. Turkey Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.6.11. Algeria
10.6.11.1. Overview
10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.11.3. Algeria Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.6.11.4. Algeria Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.6.11.5. Algeria Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.6.12. Egypt
10.6.12.1. Overview
10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.12.3. Egypt Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.6.12.4. Egypt Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.6.12.5. Egypt Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.6.13. Iran
10.6.13.1. Overview
10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.13.3. Iran Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.6.13.4. Iran Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.6.13.5. Iran Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.6.14. Qatar
10.6.14.1. Overview
10.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.14.3. Qatar Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.6.14.4. Qatar Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.6.14.5. Qatar Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
10.6.15. Rest of MEA
10.6.15.1. Overview
10.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.15.3. Rest of MEA Market Size and Forecast, By Drugs, 2020 - 2033 (US$ Million)
10.6.15.4. Rest of MEA Market Size and Forecast, By Class of Therapies, 2020 - 2033 (US$ Million)
10.6.15.5. Rest of MEA Market Size and Forecast, By Epidemiology, 2020 - 2033 (US$ Million)
11. Key Vendor Analysis- Paroxysmal Nocturnal Hemoglobinuria Industry
11.1. Competitive Benchmarking
11.1.1. Competitive Dashboard
11.1.2. Competitive Positioning
11.2. Company Profiles
11.2.1. AstraZeneca plc
11.2.2. Apellis Pharmaceuticals, Inc.
11.2.3. Swedish Orphan Biovitrum AB (Sobi)
11.2.4. Novartis AG
11.2.5. F. Hoffmann-La Roche Ltd
11.2.6. Chugai Pharmaceutical Co., Ltd.
11.2.7. Regeneron Pharmaceuticals, Inc.
11.2.8. Alnylam Pharmaceuticals, Inc.
11.2.9. Novo Nordisk A/S
11.2.10. Omeros Corporation
11.2.11. Samsung Bioepis Co., Ltd.
11.2.12. Amgen Inc.
11.2.13. Akari Therapeutics plc
11.2.14. BioCryst Pharmaceuticals, Inc.
11.2.15. NovelMed Therapeutics
11.2.16. Sanofi
11.2.17. Others
12. 360 Degree AnalystView
13. Appendix
13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- AstraZeneca plc
- Apellis Pharmaceuticals, Inc.
- Swedish Orphan Biovitrum AB (Sobi)
- Novartis AG
- Hoffmann-La Roche Ltd
- Chugai Pharmaceutical Co., Ltd.
- Regeneron Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals, Inc.
- Novo Nordisk A/S
- Omeros Corporation
- Samsung Bioepis Co., Ltd.
- Amgen Inc.
- Akari Therapeutics plc
- BioCryst Pharmaceuticals, Inc.
- NovelMed Therapeutics
- Sanofi
- Others
GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA MARKET, BY DRUGS- MARKET ANALYSIS, 2020 - 2033
- Pozelimab + Cemdisiran
- Ravulizumab (ULTOMIRIS)
- Zaltenibart (OMS906)
- Pegcetacoplan (EMPAVELI/ASPAVELI)
- Iptacopan (FABHALTA)
- Crovalimab (PIASKY)
- Eculizumab (SOLIRIS)
- Danicopan (VOYDEYA)
GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA MARKET, BY CLASS OF THERAPIES- MARKET ANALYSIS, 2020 - 2033
- MASP-3 Inhibitors
- Complement C3 Inhibitors
- Complement C5 Inhibitors
- Complement Factor B Inhibitors
- Complement Factor D Inhibitors
GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA MARKET, BY EPIDEMIOLOGY- MARKET ANALYSIS, 2020 - 2033
- Total Treated Cases
- Total Diagnosed Prevalent Cases
- Age-Specific Cases
- Gender-Specific Cases
GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Analystview Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
